Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for testosterone
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. Prostate safety is a primary concern when aging men receive testosterone replacement therapy (TRT), but little information is available regarding the effects of TRT on prostate tissue in men.To determine the effects of TRT on prostate tissue of aging men with low serum testosterone levels.Randomized, double-blind, placebo-controlled trial of 44 men, aged 44 to 78 (...) years, with screening serum testosterone levels lower than 300 ng/dL (<10.4 nmol/L) and related symptoms, conducted at a US community-based research center between February 2003 and November 2004.Participants were randomly assigned to receive 150 mg of testosterone enanthate or matching placebo intramuscularly every 2 weeks for 6 months.The primary outcome measure was the 6-month change in prostate tissue androgen levels (testosterone and dihydrotestosterone). Secondary outcome measures included 6
DHEA in elderly women and DHEA or testosterone in elderly men. Dehydroepiandrosterone (DHEA) and testosterone are widely promoted as antiaging supplements, but the long-term benefits, as compared with potential harm, are unknown.We performed a 2-year, placebo-controlled, randomized, double-blind study involving 87 elderly men with low levels of the sulfated form of DHEA and bioavailable testosterone and 57 elderly women with low levels of sulfated DHEA. Among the men, 29 received DHEA, 27 (...) received testosterone, and 31 received placebo. Among the women, 27 received DHEA and 30 received placebo. Outcome measures included physical performance, body composition, bone mineral density (BMD), glucose tolerance, and quality of life.As compared with the change from baseline to 24 months in the placebo group, subjects who received DHEA for 2 years had an increase in plasma levels of sulfated DHEA by a median of 3.4 microg per milliliter (9.2 micromol per liter) in men and by 3.8 microg per
Testosterone use in men and its effects on bone health: a systematic review and meta-analysis of randomized placebo-controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S (...) CRD summary This review evaluated the risk of adverse events associated with testosterone replacement in older men. The authors concluded that testosterone replacement is associated with a significantly higher risk of prostate events and of a haematocrit of more than 50% relative to placebo. A limited search, unclear review methodology, and the unknown quality of the primary studies limit the reliability of the conclusions. Authors' objectives To determine the risk of adverse events associated
Testosterone supplementation therapy for older men: potential benefits and risks Testosterone supplementation therapy for older men: potential benefits and risks Testosterone supplementation therapy for older men: potential benefits and risks Gruenewald D A, Matsumoto A M CRD summary This review assessed the effects of testosterone supplementation for men older than 60 without severe illness. The authors concluded that supplementation may be helpful for men with low testosterone levels (...) with or without hypogonadism. The review found only a few studies and the stated inclusion criteria were not consistently followed; hence, the conclusions should be interpreted with caution. Authors' objectives To assess the effect of testosterone supplementation therapy in older men. Searching MEDLINE was searched from 1966 to October 2001; the search terms were stated and reports published in any language were eligible. The reference lists of reviews and identified studies were checked. Manual searches
Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Testosterone therapy in HIV wasting syndrome: a systematic review and meta-analysis Testosterone therapy in HIV wasting syndrome: a systematic review and meta-analysis Testosterone therapy in HIV wasting syndrome: a systematic review and meta-analysis Kong A, Edmonds P Authors' objectives To assess the effect of testosterone compared with placebo on lean-body mass, fat-free mass or body cell mass in human immunodeficiency virus (HIV)-positive people with wasting. Searching MEDLINE, EMBASE (...) 12 weeks were eligible for inclusion. All of the included RCTs were double-blind. Specific interventions included in the review Comparisons of any type of testosterone therapy (synthetic or nonsynthetic) with placebo were eligible for inclusion. Testosterone could be given using any mode of administration, including oral, patches or intramuscular (i.m.) injection. Studies that used resistance exercise in combination with testosterone were included. The included studies used oxandrolone (5 or 15
Liquorice consumption and salivary testosterone concentrations. Liquorice consumption has been shown to substantially reduce serum testosterone concentration. An explanation for this result was that the active component in liquorice (glycyrrhizic acid) interfered with 17 beta-hydroxysteroid deyhydrogenase, which has been shown in vitro to catalyse the conversion of androstenedione to testosterone. We twice attempted to replicate this effect of liquorice but could not. We identified differences
Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis Whitsel E A, Boyko E J, Matsumoto A M, Anawalt B D, Siscovick D S Authors' objectives To determine whether intramuscular administration of testosterone esters to hypogonadal men is associated with changes in plasma lipids. Searching (...) in which pre-treatment measures were recorded on a single group of patients who later received a treatment, after which post-treatment measurements were recorded. Specific interventions included in the review Intramuscular testosterone ester. The dosage of testosterone ester ranged from 50 to 250 mg every 7 to 30 days, for a duration of 1 to 24 months. Participants included in the review Male patients with non-experimental hypogonadism. Outcomes assessed in the review Studies which reported pre
Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. Previous studies of testosterone supplementation in HIV-infected men failed to demonstrate improvement in muscle strength. The effects of resistance exercise combined with testosterone supplementation in HIV-infected men are unknown.To determine the effects of testosterone replacement with and without resistance exercise on muscle strength and body composition in HIV-infected men (...) with low testosterone levels and weight loss.Placebo-controlled, double-blind, randomized clinical trial conducted from September 1995 to July 1998 at a general clinical research center.Sixty-one HIV-infected men aged 18 to 50 years with serum testosterone levels of less than 12.1 nmol/L (349 ng/dL) and weight loss of 5% or more in the previous 6 months, 49 of whom completed the study.Participants were randomly assigned to 1 of 4 groups: placebo, no exercise (n = 14); testosterone enanthate (100 mg/wk
Oral androstenedione administration and serum testosterone concentrations in young men. Androstenedione, a steroid hormone and the major precursor to testosterone, is available without prescription and is purported to increase strength and athletic performance. The hormonal effects of androstenedione, however, are unknown.To determine if oral administration of androstenedione increases serum testosterone levels in healthy men.Open-label randomized controlled trial conducted between October 1998 (...) and April 1999.General clinical research center of a tertiary-care, university-affiliated hospital.Forty-two healthy men aged 20 to 40 years.Subjects were randomized to receive oral androstenedione (either 100 mg/d [n = 15] or 300 mg/d [n = 14]) or no androstenedione (n = 13) for 7 days.Changes in serum testosterone, androstenedione, estrone, and estradiol levels, measured by frequent blood sampling, compared among the 3 treatment groups.Mean (SE) changes in the area under the curve (AUC) for serum
Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. The ovaries provide approximately half the circulating testosterone in premenopausal women. After bilateral oophorectomy, many women report impaired sexual functioning despite estrogen replacement. We evaluated the effects of transdermal testosterone in women who had impaired sexual function after surgically induced menopause.Seventy-five women, 31 to 56 years old, who had undergone oophorectomy (...) and hysterectomy received conjugated equine estrogens (at least 0.625 mg per day orally) and, in random order, placebo, 150 microg of testosterone, and 300 microg of testosterone per day transdermally for 12 weeks each. Outcome measures included scores on the Brief Index of Sexual Functioning for Women, the Psychological General Well-Being Index, and a sexual-function diary completed over the telephone.The mean (+/-SD) serum free testosterone concentration increased from 1.2+/-0.8 pg per milliliter (4.2+/-2.8
Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. Androstenedione, a precursor to testosterone, is marketed to increase blood testosterone concentrations as a natural alternative to anabolic steroid use. However, whether androstenedione actually increases blood testosterone levels or produces anabolic androgenic effects is not known.To determine if short- and long-term oral androstenedione supplementation (...) in men increases serum testosterone levels and skeletal muscle fiber size and strength and to examine its effect on blood lipids and markers of liver function.Eight-week randomized controlled trial conducted between February and June 1998.Thirty healthy, normotestosterogenic men (aged 19-29 years) not taking any nutritional supplements or androgenic-anabolic steroids or engaged in resistance training.Twenty subjects performed 8 weeks of whole-body resistance training. During weeks 1, 2, 4, 5, 7
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. Athletes often take androgenic steroids in an attempt to increase their strength. The efficacy of these substances for this purpose is unsubstantiated, however.We randomly assigned 43 normal men to one of four groups: placebo with no exercise; testosterone with no exercise; placebo plus exercise; and testosterone plus exercise. The men received injections of 600 mg of testosterone enanthate (...) or placebo weekly for 10 weeks. The men in the exercise groups performed standardized weight-lifting exercises three times weekly. Before and after the treatment period, fat-free mass was determined by underwater weighing, muscle size was measured by magnetic resonance imaging, and the strength of the arms and legs was assessed by bench-press and squatting exercises, respectively.Among the men in the no-exercise groups, those given testosterone had greater increases than those given placebo in muscle
Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. Insulin resistance and increased ovarian cytochrome P450c17 alpha activity are both features of the polycystic ovary syndrome. P450c17 alpha, which is involved in androgen biosynthesis, has both 17 alpha-hydroxylase and 17,20-lyase activities. Increased activity of this enzyme results in exaggerated conversion of progesterone to 17 alpha (...) in the leuprolide-stimulated peak serum 17 alpha-hydroxyprogesterone concentration from 455 +/- 54 to 281 +/- 52 ng per deciliter (13.7 +/- 1.6 to 8.5 +/- 1.6 nmol per liter) (P = 0.01). The serum 17 alpha-hydroxyprogesterone values increased slightly in the placebo group. In the metformin group, the basal serum luteinizing hormone concentration decreased from 8.5 +/- 2.2 to 2.8 +/- 0.5 mlU per milliliter (P = 0.01), the serum free testosterone concentration decreased from 0.34 +/- 0.07 to 0.19 +/- 0.05 ng per
Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. In a double-blind trial oestradiol, oestradiol/testosterone, or placebo implants were assessed for their effects on psychological symptoms in women attending a menopause clinic. After two months, women receiving active treatment scored better than the placebo group on a self-rating scale of distress, on anxiety, and on depression (p less than 0.05). Postmenopausal but not perimenopausal women improved